An observational study in Behçet Disease, sponsored by Ataturk University. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by Ataturk University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Behcet Syndrome with a site in Turkey — 9 open to participants now, 10 under way, 3 of them phase 3. Behcet Syndrome · Turkey.
Among the 30 studies in Behcet Syndrome with a site in Turkey, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2023, is one of 14 observational ones, and was the 25th registered.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
Browse Behcet Syndrome studies →9 of the 30 studies in Behcet Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
ÖZLEM NUR TOK YAMAN · Sites in Turkey
Ages 18+ · Healthy volunteers
Chugai Pharmaceutical · Sites in Turkey, United States, Australia and 17 more countries
Ages 18–85
Amgen · Sites in Turkey, Greece, Israel and 1 more country
Ages 5–18
Amgen · Sites in Turkey, France, Greece and 5 more countries
Ages 2–17
University of Siena · Sites in Turkey, Algeria, Australia and 19 more countries
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 90 across 63 observational studies indexed under Behcet Syndrome.
Median enrollment 83 across the 16 interventional studies, 60 across the 13 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 30 have an industry lead sponsor. The 10 most frequent:
Ataturk University is the lead sponsor of 463 studies on the registry; 123 are open to participants now.
Ataturk University has 2 studies filed under Behcet Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Behcet Syndrome with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06925698Phase 3Marmara UniversityImmunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease | 2027-04-01 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Behcet Syndrome with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Behçet's disease (BD) is a systemic vasculitis of unknown cause, affecting mainly young adults. Vasculopathy has been reported in 16.8-51.5% of cases. Genetic, infectious factors, environmental factors, presence of autoantibodies, endothelial pathologies and hypercoagulability are responsible for the etiopathogenesis of BD. The main involvements responsible for morbidity and mortality in Behçet's disease are ocular, major cardiovascular and neurological involvements. Although there is an increased thrombotic risk in the etiopathogenesis of Behçet's disease, the cellular and molecular mechanisms are not fully understood. Although endothelial dysfunction due to inflammation has been shown to be the primary cause of vascular damage in Behçet's disease, some clinical evidence suggests that hypercoagulable states also contribute to thrombosis. The most common form of vascular involvement in Behçet's disease is deep vein thrombosis in the lower extremities. Arterial occlusion mostly affects the subclavian and pulmonary arteries. Although arterial involvement is rarer than venous involvement in Behçet's disease, morbidity and mortality are higher than venous involvement.
Although an increased thrombotic risk is mentioned in the etiopathogenesis of Behçet's disease, it is still controversial whether vasculitis or susceptibility to hypercoagulability plays a role in the pathogenesis of venous thrombosis. In addition, there are very few studies in the literature in which all thrombophilic parameters were analysed. Again, there is no recent study on this subject. The aim of our study is to determine the risk of hypercoagulability in Behçet's disease patients with vascular involvement, which has a highly mortal course.
The study was planned as a prospective case control study. The study will be conducted on 100 Behçet's patients aged 18-70 years who were diagnosed with Behçet's disease according to the International Behçet's diagnostic criteria and 100 healthy controls similar in age and gender who applied to Atatürk University Faculty of Medicine Dermatology outpatient clinic between June 2023 and September 2024. Routine clinical evaluations of all patients will be performed. Demographic characteristics (age, gender), clinical features of the disease and medications used will be recorded. Patients will be included in the study after the relevant department consultations for system involvement. Skin and mucous membrane findings seen in the last 1 month will be recorded. Blood samples will be taken from all participants and analysed in the Genetics laboratory of our hospital. DNA isolation will be performed with DNA isolation kit from peripheral blood in EDTA tube taken from patients during routine examinations. DNA samples will be stored at -20 degrees Celsius until the time of the study. After collecting the targeted number of samples, Factor II G20210A, Factor V Leiden G1691A, MTHFR (Methylene Tetra Hydro Folate Reductase) C677T, MTHFR A1298C, Factor XIII V34L, PAI (Plasminogen Activator Inhibitor-1) 4G/5G SNP (single nucleotide polymorphisms) analyses will be performed with the thrombophilia panel kit. This analysis will be performed by fragment analysis method on the ABI 3130 Genetic analyser device in the Medical Genetics Laboratory. Firstly, PCR study will be performed with the thrombophilia panel kit, the plate with patient DNA will be loaded into the capillary electrophoresis device and the analyses will be interpreted and finalised with GeneMapper software.
100 patients with Behçet's disease aged 18-70 years and 100 age- and sex-matched healthy controls
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behcet's disease
Diagnostic Test: Blood collection
Healthy control group
Diagnostic Test: Blood collection
Blood collection
Faktor II G20210A kit
Faktor II G20210A at 200 participants
Time frame: 15 months
Faktor V Leiden kit
Faktor V Leiden at 200 participants
Time frame: 15 months
G1691A kit
G1691A at 200 participants
Time frame: 15 months
MTHFR (Methylene Tetra Hydro Folate Reductase) kit
MTHFR (Methylene Tetra Hydro Folate Reductase) at 200 participants
Time frame: 15 months
C677T kit
C677T at 200 participants
Time frame: 15 months
Factor XIII kit
Factor XIII at 200 participants
Time frame: 15 months
With DNA isolation kit
PAI (Plasminogen Activator Inhibitor-1) at 200 participants
Time frame: 15 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Sep 2024, 15 months after the start.
Of 21 observational studies under Behcet Syndrome, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 81. This study's planned 15 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.